Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Parnax Lab's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parnax Lab OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Parnax Lab's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parnax Lab (BOM:506128) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Parnax Lab and its competitors. Over the past decade, Parnax Lab's OCF Margin % has ranged from 3.22 to 17.21. According to the industry distribution chart, Parnax Lab ranks #640 out of 964 companies in the Drug Manufacturers industry, placing it in the top 66.4%.
Is Parnax Lab's OCF Margin % too high?
Parnax Lab's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 17.21. Based on the distribution chart, Parnax Lab ranks #640 out of 964 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Parnax Lab has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Parnax Lab's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parnax Lab ranks #640 out of 964 companies for OCF Margin %. This places Parnax Lab in the lower half of its industry. The industry median OCF Margin % is 10.04. Historically, Parnax Lab's own OCF Margin % has ranged from 3.22 to 17.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Parnax Lab and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parnax Lab's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parnax Lab stock overvalued right now?
Based on GuruFocus' analysis, Parnax Lab (BOM:506128) is currently considered Fairly Valued. The stock's GF Value™ is ₹149.14, compared to a current price of ₹135.00 — trading 9.5% below its estimated fair value. The current OCF Margin % is 0.00%. Parnax Lab's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Parnax Lab (BOM:506128), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parnax Lab (BOM:506128) Overvalued in 2026?
Based on GuruFocus' analysis, Parnax Lab stock appears to be undervalued.
The current stock price of ₹135.00 is trading 9.5% below its estimated GF Value™ of ₹149.14.
GuruFocus considers Parnax Lab to be Fairly Valued.
Key valuation signals for BOM:506128:
OCF Margin %: 0.00%
GF Value™: ₹149.14 vs. price of ₹135.00 (9.5% below fair value)
No single metric tells the full story. See the BOM:506128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
69GF Score
Get the complete analysis for BOM:506128
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506128 has been successfully added to your 
